Some may argue that we need a strong, efficacy-driven FDA, but remember that in 1962 communication among and between clinicians, scientists, and the broader market was much less open and transparent than it is now in today's Google and YouTube era.It is unlikely that blatantly ineffective treatments will gain significant traction in such a market, especially because academic peer review and market